Little progress has been made in the pharmacological management of patients with hepatic encephalopathy, partly because it is difficult to perform clinical trials in this group of patients. A new clinical trial now suggests that polyethylene glycol is more effective than the current standard first-line therapy in these patients.
who suggest that poly ethylene glycol (PEG; a commonly used purgative for bowel preparation for colonoscopy) might be more effective than the current gold standard (lactulose) in the treatment of patients with cirrhosis and acute hepatic encephalopathy.
Lactulose is widely available, inexpensive and is the standard of care for patients with hepatic encephalopathy despite a lack of data from high-quality robust placebocontrolle d, randomized clinical trials. 4 In the past 5 years, the use of the non absorbable antibiotic rifaximin has shown promise. 5, 6 Rifaximin was initially approved for secondary prophylaxis, but is also beneficial in the treatment of overt hepatic encephalopathy; however, rifaximin is not cost-effective as a first-line therapy. [5] [6] [7] Rahimi and colleagues 3 compared the administration of 4 l of PEG with the use of lactulose for the treatment of patients with cirrhosis admitted to hospital with an acute episode of hepatic encephalopathy. The study was based on the hypothesis that a rapid catharsis of the gut using PEG might be more effective than lactulose at clearing the bowel of toxins such as ammonia (which is thought to contribute to the development of hepatic encephalopathy). The most outstanding findings were greater improvement in hepatic encephalopathy at 24 h (based on objective scoring using the hepatic encephalopathy scoring algorithm [HESA score]) and more rapid resolution of hepatic encephalopathy in patients receiving PEG therapy compared with those given lactulose (mean 24 h HESA score change of 1.5 versus 0.7 and median time to resolution of 1 day versus 2 days). The study also reported a potential reduction in the length of stay in hospital with use of PEG, but the difference was not statistically significant. Hepatic encephalopathy is not a homogenous condition, and often has nonspecific neurological symptoms and concomitant disorders, which makes it difficult to study treatment of these patients. One of their innovative solutions for the difficulties of studying mental state was the use of the HESA score, which objectifies assessments and avoids bias. The pathophysiology of hepatic encephalopathy is complex and incompletely understood. Multiple factors have been implicated, including systemic inflammation, oxidative stress, genetic factors and an altered composition of the gut microbiome. 9 However, hyperammonaemia remains central to pathogenesis, even though evidence directly correlating ammonia levels with severity of hepatic encephalopathy is limited. 9 The data from Rahimi and coworkers 3 are the first to show that ammonia levels in patients with cirrhosis and acute hepatic encephalopathy are greatly increased (mean 159 ± 70 μmol/l). Although the variability is high, these levels are similar to those seen in patients with severe acute liver failure at risk of brain herniation.
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Lactulose resulted in greater reductions in levels of ammonia than PEG, but these changes are difficult to interpret as only a single measurement was made following initiation of therapy in both treatment groups. Furthermore, levels of ammonia were only measured in a small proportion of patients and the variation was massive, which limits the ability to attribute a cause-effect relationship. Nevertheless, rapid 'gut cleansing' with PEG improved symptoms of hepatic encephalopathy faster than lactulose (1 day versus 2 days), which indicates the importance of the gut-liver-brain axis in the pathogenesis of hepatic encephalopathy.
Rahimi et al. 3 correctly identify some weaknesses in their study; most notably that it involves a fairly small cohort of patients maxkabakov/iStock/Thinkstock JANUARY 2015 | VOLUME 12 www.nature.com/nrgastro NEWS & VIEWS (25 in each treatment arm) from a single centre, which makes the data prone to possible statistical errors. Of note, PEG treatment was safe and well-tolerated with no deterioration of fluid or electrolyte status. Although the patients reportedly favoured PEG therapy, any practical issues of managing this acute treatment on the hospital ward to achieve gut catharsis in patients with an altered conscious state are not described. Unsurprisingly, patients who received PEG experienced more diarrhoea than those given lactulose; however, the number of bowel actions achieved to assess whether the response to lactulose was adequate is not reported (lactulose is usually given to produce 2-3 soft bowel actions per day, which is a surrogate marker of adequate dose). Furthermore, patients who had previously been treated with rifaximin were excluded from this study. This exclusion might have helped to preserve the integrity of the treatment arms in a study of this small size and avoid confounding variables; however, patients with a history of severe hepatic encephalopathy might be missing from the study population.
Although rifaximin is more expensive than both lactulose and PEG, it is welltolerated. 4, 7 Given its reported efficacy for treatment and prophylaxis of hepatic encephalopathy in combination with lactulose, 5, 6 it would be interesting to explore the comparative benefit of PEG or rifaximin as well as the role of combination therapies in treating acute hepatic encephalopathy. Of note, although patients in each treatment group were generally quite similar, the PEG treatment arm contained more patients whose hepatic encephalopathy was precipitated by nonadherence to previous lactulose therapy. The importance of this difference is uncertain, and a large population of patients would be required to further elucidate the effects of the difference, but this observation raises the possibility that the lactulose group had a more refractory phenotype in terms of response to therapy. This difference in phenotype might skew the results in favour of PEG, but the number of patients is small and in some cases, other potential precipitants were also identified.
The importance of the study by Rahimi et al.
3 goes beyond the clinical findings. It highlights the scarcity of rigorous clinical trial data, particularly for acute treatment of episodic hepatic encephalopathy. New effective therapies for this group of patients are an unmet need. Several other agents have attracted interest with some promising results, although data remain limited and preliminary. These agents include various therapeutic strategies, such as ammonia reduction using ornithine phenylacetate or glycerol phenylbutyrate; probiotics and nonabsorbable antibiotics to manipulate the gut microbiome; and novel approaches such as albumin infusions and albumin dialysis. 4, 9 The study by Rahimi and colleagues 3 will no doubt enable these other interventions to be tested in these acute situations by providing insight into the clinical and pathophysiological issues.
Emerging clinical trial data have started to provide important new insights into the spectrum of the clinical problem, with distinct phenotypes seen in patients with different types of hepatic encephalo pathy.
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The approach used to treat minimal hepatic encephalopathy will be different to approaches to primary and secondary prophylaxis. In turn, the treatment of patients with cirrhosis and acute hepatic encephalopathy will be different again, as shown by Rahimi and colleagues. In this era of personalized medicine, it might be that treatment should entail different targets or combinations depending on the patient's clinical presentation and pathophysiology. Ultimately, studies such as the one by Rahimi et al. 3 provide hope for the emergence of more treatment options for this challenging and notable clinical problem, for which PEG might be a useful part of our armamentarium.
